KR20150112419A - Composition for promoting bone growth comprising quince tree - Google Patents

Abstract

The present invention relates to a promoting effect of Chaenomeles sinensis on bone growth in length, and more specifically, to a pharmaceutical composition for promoting bone growth, a food composition, and a composition for animal feed, comprising Chaenomeles sinensis as an active ingredient. The composition of the present invention comprising Chaenomeles sinensis as an active ingredient shows effects of promoting the growth of a physeal plate and a long bone, thereby showing effectiveness in promoting growth and skeletal formation in an infant and a juvenile undergoing a growth perioda growth period. Furthermore, the composition of the present invention alone or with a parallel treatment of a growth hormone treatment has an advantageous effect of treating a stature growth.

Description

[0001] The present invention relates to a composition for promoting bone growth,

More particularly, the present invention relates to a pharmaceutical composition, a food composition, and an animal feed composition for promoting bone growth, which comprises an extract of Prunus mume as an active ingredient.

In recent years, there has been a growing interest in key growth factors due to the westernization of body shape and the increase in average height. If growth is defined as broad meaning, it includes increase in size and function of body organs as well as increase in kidney, but it can be considered as an increase of kidney by defining it as the concept of consultation. This increase in kidneys is mediated by skeletal metabolism, including the synthesis of cartilage tissue by various factors, such as nutrition and growth hormone, skeletal length growth, and extensive proliferation of skeletal tissues. Bone tissue is a specifically differentiated connective tissue, which is a connective tissue composed of various kinds of cells such as mesenchymal cells, cartilage cells, osteoblasts, osteoclasts, and bone marrow cells. There is a balance between the amount of bone resorption by osteoclasts and the amount of bone formation by osteoblasts. In the growing period, osteoblast-induced osteoblast production reaches its peak, and the amount of bone formation exceeds the amount of bone resorption. .

The growth plate is a group of cartilage cells with a horizontally shaped structure located at both ends of the iliac bone and located between the bone metaphysis and the epiphysis. In the cartilage, the cartilage is changed into bone by hypertrophy, extracellular matrix secretion, invasion of blood vessels and osteoclasts, and subsequent ossification of chondrocytes in the growth plate. Through the process of endochondral ossification, a new bone is continuously formed at the tip of the bony body of the growth plate, and thus the length of the iliac bone becomes longer. The growth plate is regulated by hormones such as growth hormone, insulin-like growth factor (IGF), thyroid hormone, sex hormone, glucocorticoid, and various cytokines, which eventually become ossified after puberty and fused with the surrounding bone Shin Ho Cho, 2006, Growth plate regulation of hormones, Korean Journal of Pediatric Endocrinology, Vol 11, 117-122).

On the other hand, growth hormone preparation, Ilizanov procedure, and supplement of health supplement have been used as methods for promoting growth until now. In particular, growth hormone therapy, which has been used for growth retardation in the past, has been applied to growing children and adolescents with normal height as interest in height growth has increased in recent years. However, the administration method of the above-mentioned growth hormone preparation shows excellent effect in the case of a person lacking growth hormone. However, in the majority of normal hormone secretion, many side effects such as hypertrophy of the endocrine gland, positive antibody of growth hormone, systemic allergic reaction and hypothyroidism There is a problem that can be caused. In addition, there are problems such as excessive growth period and cost of growth hormone therapy, disturbance of cancer development and other growth factors. In addition, Iridizanov surgery is an operation to increase the leg bone after it is cut, and there is a great deal of difficulty in using it for the general public in terms of patient's suffering and cost, and most of the health supplement for growth promotion is not scientifically verified.

Therefore, the efficacy of growth promotion is scientifically verified, and it is necessary to develop safe food material.

Accordingly, the present inventors studied to develop a food material having an activity of effectively promoting bone growth without side effects, and confirmed the effect of promoting the growth plate and increasing the length of iliac bone in the experimental animals to which the quince was administered, and completed the present invention.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for promoting bone growth, which comprises a quince tree as an active ingredient.

Another object of the present invention is to provide a food composition for promoting bone growth, which comprises an extract of Prunus mume as an active ingredient.

Another object of the present invention is to provide a composition for animal feed for promoting bone growth comprising quinone as an active ingredient.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for promoting bone growth comprising an extract of Prunus mume as an active ingredient.

In order to accomplish the other objects of the present invention, the present invention provides a food composition for promoting bone growth, comprising quercetin as an active ingredient.

In order to accomplish another object of the present invention, there is provided an animal feed composition for promoting bone growth comprising an extract of Prunus mume as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for promoting bone growth comprising an extract of Prunus mume as an active ingredient.

Quince tree ( Chaenomeles sinensis ) is a deciduous arboreous plant of Rosaceae Rosaceae, Cydonia sinensis , Pseudocydonia sinensis , Cydonia sinensis , and Cydonia oblonga .

The quince tree of the present invention is not limited to any part constituting the quince tree but may be preferably at least one selected from the group consisting of fruits, leaves, flowers, stems and roots of the quince tree, It can be a nut.

The fruit of the above-mentioned quince tree is the fruit of the neck ( Chaenomelis Fructus , and squash), and the neck is also referred to as a quince, a fruit, a fruit, a fragrance, a necklace, a trunk, an iron, etc. In the specification of the present invention, .

The prickly wood of the present invention can be used as it is or processed into a form that can be administered to an animal, and can be, for example, a powder, a suspension, an extract and the like.

The extract may be extracted by a known natural material extraction method, and may be extracted with at least one solvent selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, and subcritical or supercritical fluids, The organic solvent having 1 to 6 carbon atoms may be an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride chloride, hexane, cyclohexane, diethyl ether, and petroleum ether. Preferably, water or an alcohol having 1 to 6 carbon atoms can be used for extraction.

The quince extract may include a pretreatment process to increase the extraction efficiency. For example, the quince tree may be pulverized by a pulverizer.

The extraction temperature of the extract of the present invention is not particularly limited, and may be, for example, 0 ° C to 150 ° C, preferably 80 ° C to 120 ° C. The extraction time of the extract of the present invention is not particularly limited depending on the extraction temperature, and may be, for example, 10 minutes to 10 days, preferably 30 minutes to 24 hours, more preferably 1 hour to 6 hours have.

The extract of the present invention can be extracted by a known natural substance extraction method. For example, it can be extracted by cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, or heat extraction, preferably by hot water extraction or reflux cooling extraction. The extraction can be performed once to 10 times, preferably twice To 7 times.

In addition, the filtration, concentration and purification processes, the drying process, the freezing process, and the pulverization process may be arbitrarily added for ease of processing, storage and the like in the production of the quinceekera extract of the present invention.

The filtration process may be performed by a known filtration method. For example, filtration using a filter net or a microfilter, centrifugal separation and separation funnel may be used.

The concentration process may be performed by a conventional concentration process. For example, the concentration process may be performed using precipitation concentration, evaporation concentration, reduced pressure concentration, ultrafiltration, reverse osmosis, and centrifugation. The concentration in the concentration process is preferably 3 to 50 wt%, more preferably 10 to 20 wt%, and most preferably 14 to 16 wt%, based on the solid content. . ≪ / RTI >

The solid content means an active ingredient remaining when the solvent of the extract is completely evaporated. In the present invention, both the soluble solid and the non-soluble solid are included.

 The drying may be performed by a known drying method, but not limited thereto, for example, freeze drying, spray drying or hot air drying.

The pulverization process may be performed by a known pulverization method and is not limited thereto. For example, it may be pulverized by a process such as dextrin inclusion. Preferably, the extract of the present invention can be pulverized by adding crystalline cellulose as an inert excipient and hot-air drying. The addition ratio of the crystalline cellulose may be 1: 0.1 to 10, preferably 1: 0.1 to 5, and most preferably 1: 0.5 to 2, based on the weight of the solid.

The most preferred embodiment of the present invention is a neck and quince extract.

The neck and the extract are not limited thereto, but may be prepared by a hot water extraction method, preferably using water as a solvent. The ratio of the neck to the water in the hot water extraction is not particularly limited, Water may be added to the neck and neck in 3 to 20 times (weight basis). Preferably, water is added to the neck to 15 to 19 times (by weight) to increase the extraction efficiency.

In one embodiment of the present invention, the extract of Prunus persica L. extract of the present invention was prepared by adding 10 L of water to 600 g of the pulverized tree of 20-40 mesh size, and then conducting hot water extraction twice at 100 ° C for 2 hours. The hot-water extract solution was allowed to cool at room temperature and then filtered. The mixture was concentrated until the solid content reached 15 ± 1 wt% by the softening-extracting step. Crystalline cellulose was mixed with the concentrate and dried to prepare an extract powder.

The 'bone growth' of the present invention includes the size, thickness, density, length, and function of the tissue of the bone (bone), and preferably means the growth of bone length.

The composition of the present invention is effective for promoting growth of bone length and promotion of growth plate cartilage tissue growth by incorporating quercetin as an active ingredient.

This is well illustrated in the specification of the present invention.

In one embodiment of the present invention, a change in the length of the tibia was observed after administering the neck and neck for 10 days in a rat. As a result, it was confirmed that the length of the tibia was longer than that of the group treated with growth hormone.

In another embodiment of the present invention, the rats were treated with a neck and neck for 10 days, and then the changes of the growth plate tissues were observed. As a result, it was confirmed that the length of the proliferative zone and hypertrophic zone of the growth plate was increased to the level similar to that of the group treated with growth hormone.

In another embodiment of the present invention, the change in the number of chondrocyte cells activated in the cartilage tissue after BrdU staining was confirmed for 10 days in a rat. As a result, it was confirmed that the ratio of BrdU positive cells was increased, thereby confirming the promotion of chondrocyte proliferation in the neck and the administration group.

In another embodiment of the present invention, after administering the neck and neck for 10 days in a rat, the concentration of osteocalcin in the plasma was measured. As a result, it was confirmed that the concentration of osteocalcin in the plasma was increased in the neck and the administration group, and it was confirmed that the neck and the extract increased bone formation and osteoclast activity.

Accordingly, the present invention provides a pharmaceutical composition for accelerating bone growth comprising an extract of Prunus mume as an active ingredient.

The pharmaceutical composition according to the present invention may contain the germinated wood of the present invention alone or may further contain at least one pharmaceutically acceptable carrier, excipient or diluent. The term "pharmaceutically acceptable" as used herein means a non-toxic composition which is physiologically acceptable and which, when administered to humans, does not inhibit the action of the active ingredient and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, .

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may contain various drug delivery materials used for oral administration to peptide preparations. In addition, the carrier for parenteral administration may contain water, a suitable oil, a saline solution, an aqueous glucose and a glycol, and may further contain a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components. Other pharmaceutically acceptable carriers and preparations can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration Lt; / RTI >

The pharmaceutical composition of the present invention can be formulated into oral preparations or parenteral administration preparations according to the administration route as described above.

In the case of a preparation for oral administration, the composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a liquid, a gel, a syrup, a slurry, . For example, an oral preparation can be obtained by combining the active ingredient with a solid excipient, then milling it, adding suitable auxiliaries, and then processing the mixture into a granular mixture. Examples of suitable excipients include, but are not limited to, sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition of the present invention may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In the case of a preparation for parenteral administration, it can be formulated by a method known in the art in the form of injection, cream, lotion, external ointment, oil, moisturizer, gel, aerosol and nasal aspirate. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, Pa., 1995, which is a commonly known formulary for all pharmaceutical chemistries.

The total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol administered over a prolonged period of time in multiple doses. In the pharmaceutical composition of the present invention, the content of the active ingredient may be varied depending on the degree of the disease. Preferably, the total preferred dose of the pharmaceutical composition of the present invention may be from about 0.01 μg to 10,000 mg, and most preferably from 0.1 μg to 1000 mg per kg body weight of the patient per day. However, the dosage of the pharmaceutical composition may be determined depending on various factors such as the formulation method, administration route and frequency of treatment, as well as the patient's age, body weight, health condition, sex, severity of disease, diet and excretion rate, It will be possible to determine the appropriate effective dose of the composition of the present invention by those of ordinary skill in the art in view of this point. The pharmaceutical composition according to the present invention is not particularly limited to the formulation, administration route and administration method as long as the effect of the present invention is exhibited.

The present invention provides a food composition for accelerating bone growth comprising an extract of Prunus mume as an active ingredient.

The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, as a health food, the fruit of the present invention can be prepared in the form of tea, juice, and drink and then consumed, or granulated, encapsulated and powdered. In addition, the ginseng of the present invention can be prepared in the form of a composition by mixing it with a known substance or an active ingredient known to have a bone growth promoting effect. For example, the food composition of the present invention may further contain a trace amount of minerals, vitamins, lipids, saccharides, and a component having known growth promoting activity, in addition to a component of a quince tree or a quince tree extract. The minerals may include nutrients necessary for growing period such as calcium and iron. Vitamins may include vitamin C, vitamin E, vitamin B1, vitamin B2, and vitamin B6. The lipid may include alkoxyglycerol or lecithin, and the saccharides may include fructo-oligosaccharides and the like.

Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (e.g., canned fruits, bottled, jam, maalmalade, etc.), fish, meat and processed foods such as ham, Etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, , Retort food, frozen food, various kinds of seasoning (for example, soybean paste, soy sauce, sauce, etc.) and the like.

In addition, in order to use the germanium of the present invention in the form of a food additive, it may be used in the form of powder or concentrate.

The preferred content of the germinated wood in the food composition of the present invention may be 0.01 to 90%, preferably 0.1 to 50%, based on the total weight of the food, based on the total weight of the food composition.

The present invention provides an animal feed composition for promoting bone growth, comprising an extract of Prunus mume as an active ingredient.

The composition for feed according to the present invention can be produced in the form of a fermented feed, a compounded feed, a pellet form, a silage or the like. The fermented feed includes the fruit tree of the present invention and can be produced by fermenting organic matter by addition of various microorganisms or enzymes. The compound feed can be prepared by mixing various kinds of general feeds and the quince tree of the present invention. Feeds in the form of pellets can be prepared by formulating the fermented feed or the compound feed into a pelletizer. The silage can be produced by mixing the quail feed and the quince tree of the present invention and fermenting them with lactic acid bacteria.

The composition comprising the ginseng extract of the present invention as an active ingredient is effective for promoting the growth of the growth plate and the long bone and promoting the growth and skeletal formation of the young children and adolescents during the growing season. In addition, the composition of the present invention is effective alone or in combination with growth hormone therapy and concurrent therapies to treat key growth.

FIG. 1 is a schematic diagram showing the change in weight of a rat for 10 days in each administration group.
Fig. 2 shows micro-CT images of the rat tibia by administration group.
Fig. 3 shows X-ray photographs of the rat tibia by administration groups.
Fig. 4 shows the total tibia length of the rats by administration group.
FIG. 5 shows the positions and relative lengths of the proliferative zone and the hypertrophic zone in the growth plate of rats according to each administration group (control: saline administration group, GH: growth hormone administration group, neck: neck and extract administration group) .
FIG. 6 is a graph showing the length of the proliferative zone in the growth plate region of each administration group (control: saline administration group, growth: growth hormone administration group, neck: neck and extract administration group).
FIG. 7 is a graph showing the length of a hypertrophic zone in the growth plate region of each administration group (control: saline administration group, growth: growth hormone administration group, neck: neck and extract administration group).
FIG. 8 is an image of BrdU staining of cartilage tissue of each administration group.
FIG. 9 shows the ratio of BrdU positive cells in cartilage tissue of each administration group.
FIG. 10 shows the results of measurement of osteocalcin concentration in plasma in each administration group.

Hereinafter, the present invention will be described in detail.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

≪ Example 1 >

Manufacture of extracts of quince trees

The neck and neck were purchased from Dong Yang Pharmaceutical Co., Ltd. (18, Bokseok, Buk-eup, Bo-eun, Chungbuk). Using a 50-L extractor (pressurized extractor, KOREA INDUSTRIAL CO., LTD.), Weigh 20 ~ 40mesh and 600g (dry weight) of water and 10L of water. Extract 2 times at 100 ℃ for 2 hours. The hot water extract solution is allowed to stand at room temperature, cooled to room temperature, and then filtered. The concentrated extract is concentrated by using a 20 L evaporator (Rotary Evaporator, HEIDOLPH) until the solid content reaches 15 ± 1 wt% (solid content is 33.27 g by the pre-stage of soft extraction). The concentrate was mixed with crystalline cellulose having the same weight as the solid content, and then dried (100 ° C hot air drying) for 2 days in a drier to evaporate all of the water, thereby obtaining 66.79 g of the neck and extract powder.

<Experimental Example 1>

Investigation of Bone Growth Promoting Effect of Fruit Tree Extract Using Animal Model

&Lt; 1-1 > Administration of extract of corn (tree)

Three-week-old male Sprague-Dawley rats were purchased and stabilized for three days. The incubation environment was maintained at 24 ± 2 ℃ and the light and dark cycles were maintained at 12 hour intervals. The control group was orally administered saline, and the neck and the extract was orally administered once a day (the neck and extract powder prepared in Example 1 were dissolved in water). Positive group was subcutaneously injected once daily at a dose of 20 μg / kg of eutrophin (LG Life Science). The method for administering the extract of the present invention to the neck is administered to an oral cavity in all groups except Rat positive group, and all animals are administered once daily. The composition of each group is as follows.

- Control administered group: Normal saline 1ml

Positive Control: growth hormone, 20 μg / kg

- neck and administration group 200 mg / kg

After 10 days of feeding and neck and extract administration, autopsy should be done to confirm the following.

<1-2> Weight change in experimental animals

The body weight of each group in the above Experimental Example < 1-1 > and the body weight after 10 days of dietary administration were measured. Measurements were performed twice a week. The measured values were statistically processed to calculate mean value and standard deviation.

As shown in FIG. 1, 10 days of observation showed that there was almost no difference in weight in the control group, the experimental group, and the growth hormone treated group. This indicates that the weight of the mouse is not highly correlated with the effect of the neck and medication.

<1-3> Excessive bone growth and evaluation of osteoporosis toxicity

After completion of administration for 10 days in Experimental Example 1-1, osteoporosis abnormality or osteoporosis abnormality was evaluated by micro-CT method in the experimental group and the control group in which the extract of Fagus crenata according to the present invention was ingested .

The volume and thickness of the trabecular bone associated with BMD of the left tibia were verified by micro-CT. The rats were sacrificed and the left tibia was extracted and micro-CT was used to measure the shochu bone volume and the shoal bone thickness. The micro-CT system was a SKYSCAN 1172 micro-CT device and the X-ray source was 50 kV, 200 mA. The source and detector are fixed and the object rotates between them to obtain the projection data. The image has a size of 0.8um ~ 25um pixel. Micro-CT scans the entire field of view (FOV) of the left tibial neck and identifies the exact ratios by performing a partial FOV scan of the region of interest (ROI) (Chun et al 2004). Calculate the volume ratio (BV / TV,%) and trabecula thickness (Tb.Th, mm) of the trabecula inside the rectangle of the left femur of the 2D image, and calculate the ratio and thickness of the trabeculae. 27 (2006) 695-702). In vivo trabecular thickness measurement in cancellous bones: longitudinal rat imaging studies, Physiol. Meas. 27 (2006)

Percent bone volume, trabecular separation, trabecular thickness, etc., as measured by micro-CT, are mainly used as an index to assess osteoporosis presence and bone abnormality. As shown in FIG. 2 and Table 1, there is almost no difference between the groups, and it can be seen that the herbal medicines do not affect bone abnormalities or osteoporosis toxicity during the experiment.

control Neck and neck GH Percent bone volume (%) 28.66 26.09 27.87 Bone surface / volume ratio (1 / mm) 32.56 32.06 31.26 Trabecular thickness (mm) 0.13 0.13 0.13 Trabecular number (1 / mm) 2.20 2.00 2.13 Trabecular separation (mm) 0.32 0.34 0.34

<1-4> Tibia of experimental animals tibia ) Length change measurement

After 10 days of administration in the experimental example <1-1>, the left and right tibia (shinbone) of the experimental group and the control group in which the extract of Fagus crenata according to the present invention was taken were extracted and the muscle, fat, All ligaments were removed and stored in 70% alcohol, and X-ray imaging equipment (OM-FORTE-10121, DK Medical System) was used. The X-ray source was set at 55 kV, 320 mA. Tibial length was measured by X-ray of the tibia.

As shown in FIG. 3 and FIG. 4, the total tibia length of the group treated with growth hormone was increased compared with that of the control group, and the effect of increasing the total tibia length in the group treated with throat was greater than that of the control group It looked.

<1-5> Measurement of growth plate cartilage texture of experimental animals

The length of the growth plate zone is determined by autogenous staining of the cartilage tissue after H & E staining, followed by microscopy. The length of each zone is measured five times per sample and the significance is evaluated by using the average value as a representative value.

As shown in FIGS. 5 to 7, the proliferative zone and the hypertrophic zone of the growth hormone-treated group were increased compared to the control group, and the proliferative zone and the hypertrophic zone length were increased Compared with the control group.

<1-6> Chondrocytes ( chondrocyte ) Propagation effect

In order to measure the degree of chondrocyte proliferation, cartilage tissue of Rat tibia was used and brdU staining method was applied to S phase proliferative cells in the growth plate of this region. 5-Bromo-2'-deoxyuridine (product number: B9285) from Sigma was dissolved in 0.1 M ammonium hydroxide (NH ₄ OH) at a dose of 30 mg / kg. After 1 hour of the experiment, paraffin embedded tissue and staining was performed according to the method of BrdU staining kit (Invitrogen, 93-3943). BrdU positive cells were counted using a cell counter.

As a result, as shown in FIG. 8 and FIG. 9, the proportion of BrdU positive cells in the growth hormone group and the neck and the treatment group was increased to a similar level as compared with the control group. This indicates that the neck and the administration group have a chondrocyte proliferative effect.

<1-7> Osteoblast Active factor  plasma Osteocalcin ( osteocalcin ) Measure

After the blood was taken from the rat, the blood was collected from the heart and solidified, and the serum was separated to make a sample. Rat Ostecalcin / Bone Gla Protein. Total osteocalcin levels in the serum were measured using the OT / BGP ELISA Kit (Cusabio, Cat. No. CSB-E05129r).

As a result, as shown in FIG. 10, it was confirmed that plasma osteocalcine level was significantly increased in both the growth hormone-treated group and the neck-extract-administered group as compared with the control group. In particular, there was a slightly higher level of osteocalcin in the neck and the administration group compared to the growth hormone administration group. Osteocalcin is deposited in bone cells after being formed in osteoblasts, and a part of the newly formed osteocalcin is released into the blood, so that the degree of osteogenesis can be determined by measuring the blood concentration, so that the concentration of osteocalcin in plasma reflects the activity of osteoblast . As the neck and the extract of the present invention significantly increase the concentration of osteocalcin in the plasma, bone formation and osteoblast activity are increased.

As described above, the present invention relates to the effect of promoting the growth of bone length of querceta, and more particularly, to a pharmaceutical composition, a food composition, and an animal feed composition for accelerating bone growth comprising quercetin as an active ingredient.

The composition comprising the ginseng extract of the present invention as an active ingredient is effective for promoting the growth and skeletal formation of infants and adolescents at the growing stage and has the effect of promoting the growth of the growth plate and the iliac bone. And it is effective for treatment of key growth through concurrent therapy.

Claims (6)

A pharmaceutical composition for accelerating bone growth, comprising as an effective ingredient, quercetin.
A food composition for promoting bone growth, comprising quercetin as an active ingredient.
A composition for animal feed composition for promoting bone growth, comprising quercetin as an active ingredient.
4. The composition for promoting bone growth according to any one of claims 1 to 3, wherein the quince is at least one selected from the group consisting of fruit, leaves, flowers, stems and roots of a quince tree.
4. The composition for promoting bone growth according to any one of claims 1 to 3, wherein the quince is an extract of Morus alba.
6. The method of claim 5, wherein the quince extract is selected from the group consisting of water, an alcohol having 1 to 6 carbon atoms, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, petroleum ether, diethyl ether, Wherein the composition is an extract of at least one solvent selected from the group consisting of subcritical or supercritical fluids.

Images